SCHEMBL5136475

SCHEMBL5136475

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(C(O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
TSHR P16473 4/20 0.42
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
CASR P41180 2/20 0.37
HSD11B1 P28845 2/20 0.37
PDE4B Q07343 2/20 0.36
NR1H3 Q13133 1/20 0.36
CYP3A4 P08684 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649659 0.92 CASR (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL651094 0.91 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135922 0.90 C5AR1 (0.49) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135444 0.89 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136482 0.89 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5134746 0.89 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5073888 0.89 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5072370 0.87 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135825 0.87 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136214 0.87 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed